Abstract

SARS-CoV-2 virus, the causative agent of COVID-19, has produced the largest pandemic in the 21st century, becoming a very serious health problem worldwide. To prevent COVID-19 disease and infection, a large number of vaccines have been developed and approved in record time, including new vaccines based on mRNA encapsulated in lipid nanoparticles. While mRNA-based vaccines have proven to be safe and effective, they are more expensive to produce compared to conventional vaccines. A special type of mRNA vaccine is based on self-amplifying RNA (saRNA) derived from the genome of RNA viruses, mainly alphaviruses. These saRNAs encode a viral replicase in addition to the antigen, usually the SARS-CoV-2 spike protein. The replicase can amplify the saRNA in transfected cells, potentially reducing the amount of RNA needed for vaccination and promoting interferon I responses that can enhance adaptive immunity. Preclinical studies with saRNA-based COVID-19 vaccines in diverse animal models have demonstrated the induction of robust protective immune responses, similar to conventional mRNA but at lower doses. Initial clinical trials have confirmed the safety and immunogenicity of saRNA-based vaccines in individuals that had previously received authorized COVID-19 vaccines. These findings have led to the recent approval of two of these vaccines by the national drug agencies of India and Japan, underscoring the promising potential of this technology.

MeSH

Alphavirus, Sars-Cov-2, Vaccines, Rna, Messenger, Covid-19, Viruses, Immunity, Rna, Mrna Vaccines

Cited by

• Past, Present, and Future of Viral Vector Vaccine Platforms: A Comprehensive Review. Vaccines (Basel), 2025
• A second-generation, self-amplifying COVID-19 Vaccine: World's first approval and distribution in the Japanese market with vaccine hesitancy. Hum Vaccin Immunother, 2025
• Programming the immunological properties of mRNA vaccines for cancer. Nat Rev Immunol, 2026
• The advent of clinical self-amplifying RNA vaccines. Mol Ther, 2025
• Reshaping the Treatment Landscape of a Galactose Metabolism Disorder. J Inherit Metab Dis, 2025
• Single-dose replicon RNA Sudan virus vaccine uniformly protects female guinea pigs from disease. Nat Commun, 2025
• Cytokine Storms and Anaphylaxis Following COVID-19 mRNA-LNP Vaccination: Mechanisms and Therapeutic Approaches. Diseases, 2024
• Antigen Delivery Platforms for Next-Generation Coronavirus Vaccines. Vaccines (Basel), 2025
• Progress and prospects of mRNA-based drugs in pre-clinical and clinical applications. Signal Transduct Target Ther, 2024
• Revolutionizing Nanovaccines: A New Era of Immunization. Vaccines (Basel), 2025